SBP 0069330 / Camino Pharma, Sanford-Burnham Medical Research Institute, University of California - LARVOL DELTA

Preclinical and phase 1 clinical profile of SBP-9330 in development as an aid to smoking cessation (ECNP 2024) - "A modest food-effect was observed that reduced the Cmax with limited effect on AUC. In the MAD cohorts, there was an accumulation of 2.6-fold in healthy nonsmokers and 1.4-fold in healthy smokers.In Conclusion , SBP-9330 has a favorable safety and tolerability profile in healthy smokers and nonsmokers, supporting further clinical development."

P1 data • Preclinical • CNS Disorders • Nicotine Addiction • Psychiatry • Tobacco Cessation

A First-in-Human Study of SBP-9330 in Healthy Subjects (clinicaltrials.gov) - P1 | N=90 | Completed | Sponsor: Camino Pharma, LLC | Recruiting ➔ Completed

Trial completion • Tobacco Cessation

A First-in-Human Study of SBP-9330 in Healthy Subjects (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Camino Pharma, LLC | Trial completion date: Jul 2022 ➔ Jan 2023 | Trial primary completion date: Jul 2022 ➔ Jan 2023

Trial completion date • Trial primary completion date • Tobacco Cessation

A First-in-Human Study of SBP-9330 in Healthy Subjects (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: Camino Pharma, LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Tobacco Cessation

A First-in-Human Study of SBP-9330 in Healthy Subjects (clinicaltrials.gov) - P1; N=80; Not yet recruiting; Sponsor: Camino Pharma, LLC

New P1 trial • Tobacco Cessation